<DOC>
	<DOC>NCT02720536</DOC>
	<brief_summary>Extended evaluation of deferasirox film-coated tablet (FCT) formulation</brief_summary>
	<brief_title>Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation</brief_title>
	<detailed_description>Collection of additional safety and efficacy data with deferasirox film-coated tablet (FCT) in patients completing study CICL670F2201 - Provide patients enrolled and completing 24 weeks of treatment in the core study, CICL670F2201, the possibility to have additional treatment with the deferasirox FCT. - Collect additional longer term data on the safety and the tolerability of the deferasirox FCT. - Collect efficacy data on the deferasirox FCT in reduction or maintenance of iron burden as measured by serum ferritin level.</detailed_description>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Key Inclusion Criteria for subjects: Completed 24weeks of study treatment as described in the core protocol (CICL670F2201). Are deemed to be tolerating deferasirox treatment by the investigator. Provided written informed consent/assent before any studyspecific procedures are performed. For pediatric patients, consent will be obtained from parent(s) or legal patient's representative. Investigators will also obtain assent of patients according to local, regional or national guidelines. Key Exclusion for subjects: The exclusion criteria will follow those described for the core protocol CICl670F2201, which were as follows: Creatinine clearance below the contraindication limit in the locally approved prescribing information. Serum creatinine &gt; 1.5 × upper limit of normal range (ULN) at Screening Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) &gt; 5 × ULN, Significant proteinuria Patients with significant impaired gastrointestinal function or gastrointestinal disease Clinical or laboratory evidence of active Hepatitis B or Hepatitis C Patients with psychiatric or addictive disorders</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Anemia.</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Film coated tablet</keyword>
</DOC>